Warfarin Dosing for Deep Vein Thrombosis (DVT)

Initial Anticoagulation Therapy

• The American Heart Association recommends initiating warfarin at 5 mg daily and titrating to achieve a target INR of 2.0-3.0, overlapped with initial parenteral anticoagulation for a minimum of 5 days and until the INR is >2.0 for at least 24 hours, for patients with DVT 1, 2
• Intravenous unfractionated heparin (UFH) should be administered at 80 U/kg bolus followed by 18 U/kg/hour continuous infusion, adjusted to target aPTT corresponding to anti-factor Xa level of 0.3-0.7 IU/mL, for initial anticoagulation therapy in patients with DVT 1, 3
• Low molecular weight heparin (LMWH) can be used as an alternative, with enoxaparin dosed at 1 mg/kg twice daily or 1.5 mg/kg once daily, dalteparin dosed at 200 IU/kg once daily or 100 IU/kg twice daily, and tinzaparin dosed at 175 anti-Xa IU/kg once daily, for initial anticoagulation therapy in patients with DVT 1, 2, 4
• Fondaparinux can be used with weight-based dosing: <50 kg, 5 mg once daily; 50-100 kg, 7.5 mg once daily; >100 kg, 10 mg once daily, for initial anticoagulation therapy in patients with DVT 1, 2, 4

Warfarin Initiation and Monitoring

• The American Heart Association recommends a starting dose of 5 mg once daily for most patients with DVT, with consideration of lower starting doses for elderly patients or those with poor nutritional status, liver disease, or taking medications that affect warfarin metabolism 2
• The overlap period should continue for at least 5 days and until the INR is >2.0 for at least 24 hours, to minimize the risk of recurrent thrombosis in patients with DVT 1
• The target INR for patients with DVT is 2.0-3.0, as recommended by the American Heart Association 1, 2

Duration of Therapy Based on Clinical Scenario

• For patients with first DVT and reversible risk factor, the recommended duration of therapy is 3 months, as suggested by the American Heart Association 1
• For patients with first unprovoked/idiopathic DVT, the recommended duration of therapy is 6-12 months, as suggested by the American Heart Association 1
• For patients with recurrent DVT, indefinite therapy with periodic reassessment of risk/benefit is recommended, as suggested by the American Heart Association 1
• For patients with cancer-associated DVT, first-line therapy is LMWH monotherapy for at least 3-6 months or as long as cancer/chemotherapy is ongoing, as recommended by the American Heart Association and the European Society for Medical Oncology 1, 5

Special Considerations

• Cancer patients have a higher risk of recurrent VTE and bleeding, and LMWH is preferred over warfarin when possible, as recommended by the European Society for Medical Oncology 5, 6
• Drug interactions, particularly in cancer patients on chemotherapy, can affect warfarin metabolism and increase the risk of bleeding or recurrent thrombosis, as noted by the European Society for Medical Oncology 6
• Premature discontinuation of therapy increases the recurrence risk in patients with DVT, as suggested by the American Heart Association 1

INR Monitoring Frequency During DVT Treatment with Enoxaparin and Warfarin

Initial Overlap Phase (First 5-7 Days)

• The American Society of Clinical Oncology recommends starting warfarin within 24 hours of initiating enoxaparin at 5 mg daily for most patients, with close INR monitoring to ensure safe transition from parenteral to oral anticoagulation 7, 8
• The American College of Physicians suggests continuing daily or every-other-day INR monitoring until the INR reaches therapeutic range (2.0-3.0) 7, 8
• The American Heart Association recommends maintaining enoxaparin overlap for a minimum of 5 days and until INR is ≥2.0 for at least 24 hours on 2 consecutive measurements 7, 8

Rationale for Overlap Duration

• The American College of Cardiology states that the INR may reach 2.0-3.0 before adequate depletion of all vitamin K-dependent clotting factors occurs, highlighting the importance of continued enoxaparin overlap 7, 8

After Achieving Therapeutic INR

• The Mayo Clinic recommends checking INR weekly for 2-3 weeks after initial stabilization, and then extending to every 2-4 weeks once consistently stable 8, 9
• The American Society of Hematology suggests that for patients with consistently stable INRs, monitoring intervals can be extended to 6-12 weeks 9

After Dose Adjustments

• The International Society on Thrombosis and Haemostasis recommends rechecking INR within 4 weeks or sooner after warfarin dose adjustments due to out-of-range INR 9

Special Populations

• The European Society for Medical Oncology recommends more frequent monitoring for cancer patients on chemotherapy due to drug interactions affecting warfarin metabolism 10
• The American College of Clinical Pharmacy suggests considering avoiding enoxaparin or dose-adjusting for patients with renal impairment (CrCl <30 mL/min), with unfractionated heparin as a potential alternative 7, 8

Evidence‑Based Bridging of Heparin to Warfarin

Parenteral Anticoagulation Dosing

• Intravenous unfractionated heparin (UFH) – a loading dose of 80 U/kg followed by a continuous infusion of 18 U/kg/h is recommended; the infusion should be titrated to keep the aPTT ratio 1.5–2.5 (corresponding anti‑Xa 0.3–0.7 IU/mL). [Mayo Clinic] 11, 12, 13
• Subcutaneous UFH – an initial dose of 333 U/kg then 250 U/kg given twice daily provides an alternative when IV access is unavailable. [Mayo Clinic] 11
• Low‑molecular‑weight heparin (LMWH) is preferred over UFH for most patients because of more predictable pharmacokinetics and ease of dosing. [Mayo Clinic] 11

Dosing recommendations are supported by the Mayo Clinic and the American Society of Clinical Oncology. 11, 12

• Fondaparinux – weight‑adjusted dosing: < 50 kg → 5 mg daily; 50–100 kg → 7.5 mg daily; > 100 kg → 10 mg daily. [Mayo Clinic] 11, 12

Warfarin Initiation and Target INR

• Standard initial warfarin dose – 5 mg orally once daily for the majority of adults. [American College of Cardiology] 14
• Reduced starting dose (2–4 mg daily) is advised for patients ≥ 75 years, those with poor nutritional status, liver disease, or concomitant drugs that alter warfarin metabolism. [Mayo Clinic; American College of Cardiology] 11, 14
• Therapeutic INR target for venous thromboembolism – 2.0–3.0. [Mayo Clinic] 11

INR Monitoring Frequency

• In patients who have achieved a stable therapeutic INR, the monitoring interval may be extended to every 4–6 weeks at most. [European Society of Cardiology] 13

Special Populations

• Renal impairment (creatinine clearance < 30 mL/min) – LMWH accumulates and is contraindicated; UFH with aPTT‑guided dosing should be used instead. [Mayo Clinic; American Society of Clinical Oncology] 11, 12
• Cancer patients – they have a higher risk of recurrent VTE and bleeding; when feasible, LMWH monotherapy is preferred over warfarin, and INR checks should be performed more frequently because of chemotherapy‑drug interactions. [American Society of Clinical Oncology] 12
• Elderly patients (≥ 75 years) – initiate warfarin at 2–4 mg daily rather than 5 mg, and anticipate needing roughly 1 mg/day less than younger adults to reach the same INR. [American College of Cardiology] 14

Warfarin Management in Elderly Patients with Acute DVT

Target INR Range

• In elderly patients (≥ 70 years) with acute deep‑vein thrombosis, the therapeutic International Normalized Ratio (INR) should be maintained between 2.0 and 3.0, with an optimal target of 2.5. This recommendation is based on data published in the Journal of the American Geriatrics Society (2000) [15][16].

Fixed Low‑Dose Warfarin Ineffectiveness

• A fixed low dose of 1 mg warfarin is ineffective for prophylaxis or treatment of DVT in the elderly, as demonstrated in the same JAGS (2000) studies [15][16].